Core Technology Features of AdaptiM3D
AdaptiM3D utilises advanced 3D printing technology specifically designed for pharmaceutical applications. Our system allows for precise dosing and rapid formulation adjustments without the need for traditional manufacturing processes and lengthy development times.
The AdaptiM3D technology reduces the manufacturing timeline, footprint and cost while enabling production of advanced dose forms
AdaptiM3D has developed a novel “table top” 3D printing machine that can replace multiple manufacturing steps with a single integrated process that can supply clinical trial volumes rapidly, generating cost savings and additional “on-patent” sales for pharmaceutical firms; using this highly novel approach several processes are replaced with one and a factory is replaced with a single, small manufacturing room.
This technology provides a step change, which is analogous to the switch from large run printing processes to digital printing. AdaptiM3D will be able to formulate a new drug product within 1-2 weeks and to manufacture batches within 24-72 hours, assuming that a suitable formulation has been developed.
In comparison, standard tablet formulation processes take 3-6 months and manufacturing processes take 1-3 months, typically leading to a 6 months delay, if dose reformulation is required during a clinical trial. This patent pending technology combined with the team’s formulation expertise can provide a 3 to 5-2-3 month time saving or a benefit of up to tens of millions of dollars per trial.
The AdaptiM3D technology eliminates multiple process steps - allowing a factory to be replaced with a single manufacturing room
3D Printing
Each process step requires machine cleaning and preparation before manufacturing, and QC / QA checks and approvals after processing, which add substantially to total elapsed times.